John Otrompke, BA, JD

News

TKD1 Insertions Carry Negative Prognostic Impact in the Treatment of AML With Midostaurin

03/10/2022

According to the results of a large retrospective study, multi-targeted protein kinase inhibitor midostaurin exerted a significant benefit for patients with AML, but only for those with mutations solely in the cytoplasmic JMD of the FLT3...

According to the results of a...

03/10/2022

Oncology

News

Frontline Obinutuzumab Plus Ibrutinib and Venetoclax Safe, Effective in High-Risk CLL: CLL2-GIVe Trial

04/26/2022

John Otrompke , BA, JD;

More than half of high-risk patients with CLL treated with frontline obinutuzumab, ibrutinib, and venetoclax in the ongoing CLL2-GIVe trial experienced a complete response at cycle 15, meeting the trial’s primary end point.

More than half of high-risk...

04/26/2022

Oncology

News

Nivolumab Plus Ipilimumab Superior to Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma

06/13/2022

John Otrompke , BA, JD;

Nivolumab plus ipilimumab demonstrated durable clinical benefit over sunitinib for the first-line treatment of patients with advanced renal cell carcinoma after 5 years of follow-up, according to findings from the CheckMate 214 trial.

Nivolumab plus ipilimumab...

06/13/2022

Oncology

News

Adjuvant Capecitabine Improves Survival in Biliary Tract Cancer: Findings From the BILCAP Study

04/14/2022

John Otrompke , BA, JD;

Long-term data from the BILCAP study confirm the role of capecitabine as the adjuvant standard of care in curatively resected biliary tract cancer.

Long-term data from the BILCAP...

04/14/2022

Oncology

News

Venetoclax Consolidation Associated With Increased Adverse Events, Does Not Reduce Risk of Relapse in CLL

04/26/2022

John Otrompke , BA, JD;

Study findings suggest venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated CLL is associated with increased adverse events and offers no relapse-free advantage.

Study findings suggest...

04/26/2022

Oncology

News

Triplet vs Doublet Therapy for Older/Unfit Patients With FLT3-Mutated AML

07/07/2022

John Otrompke , BA, JD;

Study findings reveal triplet therapy with lower intensity chemotherapy, a FLT3 inhibitor, and venetoclax may be an effective first-line regimen compared to lower intensity chemotherapy plus a FLT3 inhibitor alone for older/unfit patients...

Study findings reveal triplet...

07/07/2022

Oncology

Conference Coverage

Experimental Bioactive Cream DS101 Demonstrates Efficacy at Reducing Rosacea Symptoms

03/26/2022

John Otrompke , BA, JD;

In the study, researchers evaluated the progress of 20 adults with mild-to-moderate rosacea and sensitive skin who applied DS101 cream twice-daily on their entire face for 12 weeks.

In the study, researchers...

03/26/2022

The Dermatologist

News

Adding Carboplatin to Neoadjuvant Chemotherapy Improves EFS in Triple–Negative Breast Cancer

04/27/2022

John Otrompke , BA, JD;

The addition of carboplatin to neoadjuvant paclitaxel was associated with improved EFS in patients with triple–negative breast cancer, according to long-term follow-up data from the phase 3 BrighTNess trial.

The addition of carboplatin to...

04/27/2022

Oncology

News

Tisagenlecleucel Associated With Improved Response Rates, Reduced Risk of Death vs Historical Treatments for DLBCL

06/14/2022

John Otrompke , BA, JD;

Third-line or later treatment with tisagenlecleucel is associated with significantly higher response rates and significantly lower risk of death compared with historical control treatments for patients with relapsed/refractory DLBCL.

Third-line or later treatment...

06/14/2022

Oncology

News

CAR-T Therapy Shows Efficacy at Eliminating Residual Disease in B-ALL

03/10/2022

John Otrompke , BA, JD;

In a small clinical trial where patients with B-ALL with MRD were treated with CD19 CAR T-cell therapy, 85.7% responded, converting to MRD-negativity.

In a small clinical trial where...

03/10/2022

Oncology